What is Synthelis?
Synthelis operates at the intersection of advanced biochemistry and industrial application, specializing in cell-free protein expression. Since its inception in 2011, the firm has addressed the inherent limitations of traditional biological manufacturing by providing rapid, flexible, and scalable solutions. Their proprietary technology platform is designed to support the rigorous demands of the biomedical and biopharmaceutical industries, enabling researchers to overcome bottlenecks in protein production and assay development.
By focusing on high-precision bioluminescence and the synthesis of complex proteins, Synthelis provides a vital service to organizations tasked with developing new biological tests and therapeutic candidates. Their market position is defined by a commitment to technical excellence and a modular approach that allows for seamless integration into existing R&D workflows, effectively bridging the gap between laboratory-scale discovery and industrial-scale production.
How much funding has Synthelis raised?
Synthelis has raised a total of $826K across 1 funding round:
Unspecified
$826K
Unspecified (2014): $826K with participation from Sud Rhone-Alpes Capital, Grenoble Business Angels, and Rhu00f4ne-Alpes Cru00e9ation
Key Investors in Synthelis
Sud Rhone-Alpes Capital
A regional financial institution providing comprehensive banking and investment services, with a focus on supporting sustainable economic development and local innovation projects.
Grenoble Business Angels
A venture capital and private equity firm based in Grenoble, France, dedicated to fostering entrepreneurial growth and supporting early-stage innovative companies.
Rhone Alpes Creation
A specialized venture capital and private equity firm focused on the Auvergne-Rhone-Alpes region, providing strategic financial backing to high-potential enterprises.
What's next for Synthelis?
With the successful closure of this major strategic investment, Synthelis is poised to deepen its penetration into international markets while refining its core protein expression technologies. The strategic roadmap likely involves increasing production capacity to meet the rising demand for high-purity biomolecules in drug discovery pipelines. Furthermore, the company is expected to leverage its established partnerships to enhance its portfolio of biological testing solutions, ensuring that its proprietary methods remain at the forefront of the biotechnology sector.
The focus moving forward will be on operational scaling and the commercialization of new research tools that address the evolving challenges of the life sciences industry. By maintaining a rigorous focus on innovation and technical reliability, Synthelis is well-equipped to sustain its growth trajectory and continue providing essential infrastructure for the next generation of biological advancements.
